true
1994-06-01
2024-03-27
220
ADA1A_HUMAN
Cloning, functional expression and tissue distribution of human cDNA for the alpha 1C-adrenergic receptor.
Hirasawa A.
Horie K.
Tanaka T.
Takagaki K.
Murai M.
Yano J.
Tsujimoto G.
doi:10.1006/bbrc.1993.2130
1993
Biochem. Biophys. Res. Commun.
195
902-909
NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] (ISOFORM 1)
VARIANT ARG-347
Prostate
Cloning, expression and characterization of human alpha adrenergic receptors alpha 1a, alpha 1b and alpha 1c.
Weinberg D.H.
Trivedi P.
Tan C.P.
Mitra S.
Perkins-Barrow A.
Borkowski D.
Strader C.D.
Bayne M.
doi:10.1006/bbrc.1994.1845
1994
Biochem. Biophys. Res. Commun.
201
1296-1304
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)
VARIANT ARG-347
Heart
The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.
Forray C.
Bard J.A.
Wetzel J.M.
Chiu G.
Shapiro E.
Tang R.
Lepor H.
Hartig P.R.
Weinshank R.L.
Branchek T.A.
Gluchowski C.
1994
Mol. Pharmacol.
45
703-708
NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORM 1)
Hippocampus
Lymphocyte
The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types.
Tseng-Crank J.
Kost T.
Goetz A.
Hazum S.
Roberson K.M.
Haizlip J.
Godinot N.
Robertson C.N.
Saussy D.
doi:10.1111/j.1476-5381.1995.tb16640.x
1995
Br. J. Pharmacol.
115
1475-1485
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)
VARIANT ARG-347
Cloning, functional expression and tissue distribution of human alpha 1c-adrenoceptor splice variants.
Hirasawa A.
Shibata K.
Horie K.
Takei Y.
Obika K.
Tanaka T.
Muramoto N.
Takagaki K.
Yano J.
Tsujimoto G.
doi:10.1016/0014-5793(95)00330-c
1995
FEBS Lett.
363
256-260
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 2 AND 3)
VARIANT ARG-347
TISSUE SPECIFICITY
Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues.
Schwinn D.A.
Johnston G.I.
Page S.O.
Mosley M.J.
Wilson K.H.
Worman N.P.
Campbell S.
Fidock M.D.
Furness L.M.
Parry-Smith D.J.
Peter B.
Bailey D.S.
1995
J. Pharmacol. Exp. Ther.
272
134-142
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)
VARIANT ARG-347
Molecular cloning, genomic characterization and expression of novel human alpha1A-adrenoceptor isoforms.
Chang D.J.
Chang T.K.
Yamanishi S.S.
Salazar F.H.R.
Kosaka A.H.
Khare R.
Bhakta S.
Jasper J.R.
Shieh I.-S.
Lesnick J.D.
Ford A.P.D.W.
Daniels D.V.
Clarke D.E.
Bach C.T.
Chan H.W.
doi:10.1016/s0014-5793(98)00024-6
1998
FEBS Lett.
422
279-283
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 4)
TISSUE SPECIFICITY
Truncated isoforms inhibit [3H]prazosin binding and cellular trafficking of native human alpha1A-adrenoceptors.
Coge F.
Guenin S.P.
Renouard-Try A.
Rique H.
Ouvry C.
Fabry N.
Beauverger P.
Nicolas J.P.
Galizzi J.-P.
Boutin J.A.
Canet E.
doi:10.1042/bj3430231
1999
Biochem. J.
343
231-239
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 5; 6; 7; 8 AND 9)
Liver
RT-PCR cloning and sequence analysis of adrenergic receptor subtype-alpha-1a cDNA from human prostrate cell-line DU-145.
Banerjee A.G.N.
Aarti A.
2001-06
EMBL/GenBank/DDBJ
NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1)
Genome-wide discovery and analysis of human seven transmembrane helix receptor genes.
Suwa M.
Sato T.
Okouchi I.
Arita M.
Futami K.
Matsumoto S.
Tsutsumi S.
Aburatani H.
Asai K.
Akiyama Y.
2001-07
EMBL/GenBank/DDBJ
NUCLEOTIDE SEQUENCE [GENOMIC DNA]
cDNA clones of human proteins involved in signal transduction sequenced by the Guthrie cDNA resource center (www.cdna.org).
Kopatz S.A.
Aronstam R.S.
Sharma S.V.
2003-09
EMBL/GenBank/DDBJ
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)
Complete sequencing and characterization of 21,243 full-length human cDNAs.
Ota T.
Suzuki Y.
Nishikawa T.
Otsuki T.
Sugiyama T.
Irie R.
Wakamatsu A.
Hayashi K.
Sato H.
Nagai K.
Kimura K.
Makita H.
Sekine M.
Obayashi M.
Nishi T.
Shibahara T.
Tanaka T.
Ishii S.
Yamamoto J.
Saito K.
Kawai Y.
Isono Y.
Nakamura Y.
Nagahari K.
Murakami K.
Yasuda T.
Iwayanagi T.
Wagatsuma M.
Shiratori A.
Sudo H.
Hosoiri T.
Kaku Y.
Kodaira H.
Kondo H.
Sugawara M.
Takahashi M.
Kanda K.
Yokoi T.
Furuya T.
Kikkawa E.
Omura Y.
Abe K.
Kamihara K.
Katsuta N.
Sato K.
Tanikawa M.
Yamazaki M.
Ninomiya K.
Ishibashi T.
Yamashita H.
Murakawa K.
Fujimori K.
Tanai H.
Kimata M.
Watanabe M.
Hiraoka S.
Chiba Y.
Ishida S.
Ono Y.
Takiguchi S.
Watanabe S.
Yosida M.
Hotuta T.
Kusano J.
Kanehori K.
Takahashi-Fujii A.
Hara H.
Tanase T.-O.
Nomura Y.
Togiya S.
Komai F.
Hara R.
Takeuchi K.
Arita M.
Imose N.
Musashino K.
Yuuki H.
Oshima A.
Sasaki N.
Aotsuka S.
Yoshikawa Y.
Matsunawa H.
Ichihara T.
Shiohata N.
Sano S.
Moriya S.
Momiyama H.
Satoh N.
Takami S.
Terashima Y.
Suzuki O.
Nakagawa S.
Senoh A.
Mizoguchi H.
Goto Y.
Shimizu F.
Wakebe H.
Hishigaki H.
Watanabe T.
Sugiyama A.
Takemoto M.
Kawakami B.
Yamazaki M.'
Watanabe K.
Kumagai A.
Itakura S.
Fukuzumi Y.
Fujimori Y.
Komiyama M.
Tashiro H.
Tanigami A.
Fujiwara T.
Ono T.
Yamada K.
Fujii Y.
Ozaki K.
Hirao M.
Ohmori Y.
Kawabata A.
Hikiji T.
Kobatake N.
Inagaki H.
Ikema Y.
Okamoto S.
Okitani R.
Kawakami T.
Noguchi S.
Itoh T.
Shigeta K.
Senba T.
Matsumura K.
Nakajima Y.
Mizuno T.
Morinaga M.
Sasaki M.
Togashi T.
Oyama M.
Hata H.
Watanabe M.'
Komatsu T.
Mizushima-Sugano J.
Satoh T.
Shirai Y.
Takahashi Y.
Nakagawa K.
Okumura K.
Nagase T.
Nomura N.
Kikuchi H.
Masuho Y.
Yamashita R.
Nakai K.
Yada T.
Nakamura Y.'
Ohara O.
Isogai T.
Sugano S.
doi:10.1038/ng1285
2004
Nat. Genet.
36
40-45
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)
Cerebellum
NHLBI resequencing and genotyping service (RS&G)
2007-12
EMBL/GenBank/DDBJ
NUCLEOTIDE SEQUENCE [GENOMIC DNA]
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team
doi:10.1101/gr.2596504
2004
Genome Res.
14
2121-2127
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1)
VARIANT ARG-347
Identification of alpha 1-adrenoceptor subtypes present in the human prostate.
Faure C.
Pimoule C.
Vallancien G.
Langer S.Z.
Graham D.
doi:10.1016/0024-3205(94)90031-0
1994
Life Sci.
54
1595-1605
NUCLEOTIDE SEQUENCE [MRNA] OF 52-400 (ISOFORMS 1/2/3/4)
TISSUE SPECIFICITY
VARIANT ARG-347
Nuclear alpha1-adrenergic receptors signal activated ERK localization to caveolae in adult cardiac myocytes.
Wright C.D.
Chen Q.
Baye N.L.
Huang Y.
Healy C.L.
Kasinathan S.
O'Connell T.D.
doi:10.1161/circresaha.108.176024
2008
Circ. Res.
103
992-1000
SUBCELLULAR LOCATION
FUNCTION
Nuclear localization drives alpha1-adrenergic receptor oligomerization and signaling in cardiac myocytes.
Wright C.D.
Wu S.C.
Dahl E.F.
Sazama A.J.
O'Connell T.D.
doi:10.1016/j.cellsig.2011.11.014
2012
Cell. Signal.
24
794-802
SUBCELLULAR LOCATION
SUBUNIT
FUNCTION
MUTAGENESIS OF LYS-334; LYS-335; ARG-342; ARG-348 AND LYS-349
MURC/Cavin-4 facilitates recruitment of ERK to caveolae and concentric cardiac hypertrophy induced by alpha1-adrenergic receptors.
Ogata T.
Naito D.
Nakanishi N.
Hayashi Y.K.
Taniguchi T.
Miyagawa K.
Hamaoka T.
Maruyama N.
Matoba S.
Ikeda K.
Yamada H.
Oh H.
Ueyama T.
doi:10.1073/pnas.1315359111
2014
Proc. Natl. Acad. Sci. U.S.A.
111
3811-3816
INTERACTION WITH CAVIN4
SUBCELLULAR LOCATION
Alpha 1a-adrenoceptor polymorphism: pharmacological characterization and association with benign prostatic hypertrophy.
Shibata K.
Hirasawa A.
Moriyama N.
Kawabe K.
Ogawa S.
Tsujimoto G.
doi:10.1111/j.1476-5381.1996.tb15552.x
1996
Br. J. Pharmacol.
118
1403-1408
VARIANT ARG-347
Alpha 1A-adrenergic receptor polymorphism and vascular response.
Sofowora G.G.
Dishy V.
Landau R.
Xie H.G.
Prasad H.C.
Byrne D.W.
Smiley R.M.
Kim R.B.
Wood A.J.
Stein C.M.
doi:10.1016/j.clpt.2004.02.006
2004
Clin. Pharmacol. Ther.
75
539-545
VARIANT ARG-347
The consensus coding sequences of human breast and colorectal cancers.
Sjoeblom T.
Jones S.
Wood L.D.
Parsons D.W.
Lin J.
Barber T.D.
Mandelker D.
Leary R.J.
Ptak J.
Silliman N.
Szabo S.
Buckhaults P.
Farrell C.
Meeh P.
Markowitz S.D.
Willis J.
Dawson D.
Willson J.K.V.
Gazdar A.F.
Hartigan J.
Wu L.
Liu C.
Parmigiani G.
Park B.H.
Bachman K.E.
Papadopoulos N.
Vogelstein B.
Kinzler K.W.
Velculescu V.E.
doi:10.1126/science.1133427
2006
Science
314
268-274
VARIANT [LARGE SCALE ANALYSIS] TRP-40
Frameshift.
Sequence problems.
2.92
A=1-227
A=262-371
3.52
A=1-227
A=262-371
3.35
A=1-234
A=276-371
2.60
R=15-350
3.10
R=15-350
27
33
4-Methoxyamphetamine
Acepromazine
Alfuzosin
Amitriptyline
Amoxapine
Amphetamine
Apraclonidine
Aranidipine
Aripiprazole
Aripiprazole lauroxil
Arotinolol
Asenapine
Benzphetamine
Bevantolol
Bromocriptine
Buspirone
Cabergoline
Cariprazine
Carvedilol
Chlorpromazine
Cirazoline
Clonidine
Clozapine
Dapiprazole
Desipramine
Dextroamphetamine
Dihydroergocornine
Dihydroergocristine
Dihydroergotamine
Dipivefrin
DL-Methylephedrine
Dobutamine
Dosulepin
Doxazosin
Doxepin
Dronedarone
Droperidol
Droxidopa
Ephedrine
Epicept NP-1
Epinastine
Epinephrine
Ergoloid mesylate
Ergometrine
Ergotamine
Escitalopram
Etoperidone
Fenoldopam
Flupentixol
Haloperidol
Iloperidone
Imipramine
Indigotindisulfonic acid
Indoramin
Isometheptene
Labetalol
Lamotrigine
Lofexidine
Lorpiprazole
Loxapine
Maprotiline
Mephentermine
Metaraminol
Methotrimeprazine
Methoxamine
Mianserin
Midodrine
Mirtazapine
Moxisylyte
Naphazoline
Nefazodone
Nicardipine
Nicergoline
Niguldipine
Norepinephrine
Nortriptyline
Ocaperidone
Olanzapine
Oxymetazoline
Paliperidone
Paroxetine
Pergolide
Perospirone
Phendimetrazine
Phenoxybenzamine
Phentolamine
Phenylephrine
Pipamperone
Pizotifen
Prazosin
Prochlorperazine
Promazine
Promethazine
Propiomazine
Propiverine
Pseudoephedrine
Quetiapine
Quinidine
R450
Racepinephrine
Ranolazine
Risperidone
Ropinirole
Sertindole
Silodosin
Synephrine
Tamsulosin
Terazosin
Tetryzoline
Thioproperazine
Thioridazine
Tiapride
Tizanidine
Tolazoline
Trazodone
Trifluoperazine
Trimipramine
Verapamil
Xylometazoline
Ziprasidone
Zuclopenthixol
3 sites, No reported glycans
3 sites
416 antibodies from 38 providers
human
ADRA1A
Tissue enhanced (adipose tissue, liver)
gene
Eukaryota
Adrenoceptors
G alpha (q) signalling events
G alpha (12/13) signalling events
7 hits in 1158 CRISPR screens
Tclin
Protein
Expressed in right lobe of liver and 109 other cell types or tissues
baseline and differential
7tmA_alpha1A_AR
Rhodopsin 7-helix transmembrane proteins
ADR_fam
ADRA1A_rcpt
GPCR_Rhodpsn
GPCR_Rhodpsn_7TM
ADRENERGIC RECEPTOR-RELATED G-PROTEIN COUPLED RECEPTOR
ALPHA-1A ADRENERGIC RECEPTOR
7tm_1
ADRENERGICR
ADRENRGCA1AR
GPCRRHODOPSN
7TM_GPCR_Srsx
Family A G protein-coupled receptor-like
G_PROTEIN_RECEP_F1_1
G_PROTEIN_RECEP_F1_2
HS
Alpha-1A adrenergic receptor
Alpha-1A adrenoreceptor
Alpha-1A adrenoceptor
Alpha-1C adrenergic receptor
Alpha-adrenergic receptor 1c
ADRA1A
ADRA1C
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Homo- and heterooligomer. Heterooligomerizes with ADRA1B homooligomers in cardiac myocytes (PubMed:22120526). Interacts with CAVIN4 (PubMed:24567387).
Location at the nuclear membrane facilitates heterooligomerization and regulates ERK-mediated signaling in cardiac myocytes. Colocalizes with GNAQ, PLCB1 as well as LAP2 at the nuclear membrane of cardiac myocytes.
Expressed in heart, brain, liver and prostate, but not in kidney, lung, adrenal, aorta and pituitary. Within the prostate, expressed in the apex, base, periurethral and lateral lobe. Isoform 4 is the most abundant isoform expressed in the prostate with high levels also detected in liver and heart.
C-terminal Ser or Thr residues may be phosphorylated.
May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay.
Belongs to the G-protein coupled receptor 1 family. Adrenergic receptor subfamily. ADRA1A sub-subfamily.
Alpha-1A adrenergic receptor
51487
1
466
Extracellular
27
Helical; Name=1
28
51
Cytoplasmic
52
64
Helical; Name=2
65
88
Extracellular
89
99
Helical; Name=3
100
122
Cytoplasmic
123
143
Helical; Name=4
144
167
Extracellular
168
181
Helical; Name=5
182
205
Cytoplasmic
206
273
Helical; Name=6
274
297
Extracellular
298
305
Helical; Name=7
306
329
Cytoplasmic
330
Nuclear localization signal
334
349
Phosphoserine; by PKA
215
S-palmitoyl cysteine
345
N-linked (GlcNAc...) asparagine
7
N-linked (GlcNAc...) asparagine
13
N-linked (GlcNAc...) asparagine
22
176
In isoform 8.
DEVSLCHQAGVQWHDLGSLQPPPPGFKRFSCLSLPSSWDYRDVPPGRRHQAQLIFVFLVETGFHHVGQDDLDLLTS
295
In isoform 6.
DEETEAQEGKNDSPSFKQPVHHAAVLGLEVMEKENLEGVSRKDTCGVW
342
In isoform 9.
THTHDMKPASRPRLLSLLPKEGEHETHHWSCDPLSLESTPGAQEPCLTLGFTSLSSIHLTKAQIQHVTVTDTGKTVT
296
In isoform 7.
TYILKYDVLFWRKGLSVCTRLRERKEIKN
324
In isoform 5.
KS
In isoform 5.
In isoform 7.
325
In isoform 6.
343
In isoform 2.
TKSRSVTRLECSGMILAHCNLRLPGSRDSPASASQAAGTTGMCHQADATRPS
424
In isoform 4.
RGMDCRYFTKNCREHIKHVNFMMPPWRKGSEC
In isoform 3.
GHTPMT
429
In isoform 3.
430
In a breast cancer sample; somatic mutation.
W
40
S
200
R
347
R
414
D
465
Abolishes targeting to the nuclear membrane of cardiac myocytes; when associated with A-335; A-342; A-348 and A-349.
A
Abolishes targeting to the nuclear membrane of cardiac myocytes; when associated with A-334; A-342; A-348 and A-349.
A
335
Abolishes targeting to the nuclear membrane of cardiac myocytes; when associated with A-334; A-335; A-348 and A-349.
A
Abolishes targeting to the nuclear membrane of cardiac myocytes; when associated with A-334; A-335; A-342 and A-349.
A
348
Abolishes targeting to the nuclear membrane of cardiac myocytes; when associated with A-334; A-335; A-342 and A-348.
A
C
43
T
129
H
130
A
185
C
338
P
359
A
384
G
387
R
390
E
431
E
437
C
442
L
453
Q
302
false
3
CRELD1
1995-11-01
2
51487
24dc3b59f9707089e81ee874ce901500
1
Alpha 1c-1
Alpha(1A-1)
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPDFKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTLHPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCTTARVRSKSFLQVCCCVGPSTPSLDKNHQVPTIKVHTISLSENGEEV
2
Alpha 1c-2
Alpha(1A-2)
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPDFKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTLHPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCTTARTKSRSVTRLECSGMILAHCNLRLPGSRDSPASASQAAGTTGMCHQADATRPS
3
Alpha 1c-3
Alpha(1A-3)
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPDFKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTLHPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCTTARGHTPMT
4
Alpha(1A-4)
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGSFFPDFKPSETVFKIVFWLGYLNSCINPIIYPCSSQEFKKAFQNVLRIQCLCRKQSSKHALGYTLHPPSQAVEGQHKDMVRIPVGSRETFYRISKTDGVCEWKFFSSMPRGSARITVSKDQSSCTTARRGMDCRYFTKNCREHIKHVNFMMPPWRKGSEC
5
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGKS
6
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIDEETEAQEGKNDSPSFKQPVHHAAVLGLEVMEKENLEGVSRKDTCGVW
7
2b/3b
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGTYILKYDVLFWRKGLSVCTRLRERKEIKN
8
2c
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIDEVSLCHQAGVQWHDLGSLQPPPPGFKRFSCLSLPSSWDYRDVPPGRRHQAQLIFVFLVETGFHHVGQDDLDLLTS
9
3c
MVFLSGNASDSSNCTQPPAPVNISKAILLGVILGGLILFGVLGNILVILSVACHRHLHSVTHYYIVNLAVADLLLTSTVLPFSAIFEVLGYWAFGRVFCNIWAAVDVLCCTASIMGLCIISIDRYIGVSYPLRYPTIVTQRRGLMALLCVWALSLVISIGPLFGWRQPAPEDETICQINEEPGYVLFSALGSFYLPLAIILVMYCRVYVVAKRESRGLKSGLKTDKSDSEQVTLRIHRKNAPAGGSGMASAKTKTHFSVRLLKFSREKKAAKTLGIVVGCFVLCWLPFFLVMPIGTHTHDMKPASRPRLLSLLPKEGEHETHHWSCDPLSLESTPGAQEPCLTLGFTSLSSIHLTKAQIQHVTVTDTGKTVT
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true
true